<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00303420</url>
  </required_header>
  <id_info>
    <org_study_id>B2003:119</org_study_id>
    <nct_id>NCT00303420</nct_id>
  </id_info>
  <brief_title>Alteplase for Blood Flow Restoration in Hemodialysis Catheters</brief_title>
  <official_title>Alteplase for Blood Flow Restoration in Hemodialysis Catheters: A Randomized Prospective Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Manitoba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Manitoba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      We are investigating a new way of administering alteplase to remove clots from hemodialysis
      catheters. Currently, alteplase is left to dwell inside the catheter between dialysis
      treatments to dissolve the clot and restore blood flow through the catheter. We have
      developed a new way to administer alteplase by advancing it to the tip of the catheter at
      regular 10 minute intervals. We hypothesize that our new &quot;push&quot; protocol will dissolve clots
      in hemodialysis catheters better and faster than the current dwell method.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Central venous catheters are commonly used for vascular access in the hemodialysis
      population. A common complication is low / no blood flow through the catheter due to clots.
      These are serious situations because patients may miss dialysis sessions and suffer
      significant morbidity. In an attempt to dissolve the clots and restore blood flow,
      thrombolytics are frequently instilled into the catheters between dialysis sessions .
      However, we have developed and new &quot;push&quot; protocol that advances fresh thrombolytic
      (alteplase) to the tip of the catheter in order to facilitate more effective and faster
      removal of the clot. We hypothesize that our new &quot;push&quot; protocol will dissolve clots in
      hemodialysis catheters better and faster than the current dwell method.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Unable to enrol enough people to achieve the full sample size
  </why_stopped>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with pre-thrombolytic blood flows less than 200 ml/min achieving a &quot;sustainable&quot; post thrombolytic blood flow &gt; or = 300 ml/min.</measure>
    <time_frame>4 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Highest recorded &quot;sustainable&quot; blood flow (ml/min) pre- and post- thrombolytic administration.</measure>
    <time_frame>4 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Kt/V from the treatment before thrombolytic administration compared to the treatment after thrombolytic administration.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in &quot;litres processed / time&quot; from the treatment before thrombolytic administration compared to the treatment after thrombolytic administration.</measure>
    <time_frame>72 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events including major bleeding within 24 hours of alteplase administration</measure>
    <time_frame>30 days post-last dose</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">180</enrollment>
  <condition>Thrombosis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Alteplase used by normal dwell procedure</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Alteplase given by an new &quot;push&quot; protocol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Alteplase &quot;push&quot; protocol</intervention_name>
    <description>alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.</description>
    <arm_group_label>2</arm_group_label>
    <other_name>CathFlo</other_name>
    <other_name>alteplase</other_name>
    <other_name>rTPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase dwell arm</intervention_name>
    <description>alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Cathflo</other_name>
    <other_name>alteplase</other_name>
    <other_name>rTPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adults &gt; 18 yrs old

          2. Hemodialysis patients

          3. Vascular access with a permanent catheter

          4. No prior rt-PA use in the catheter over the previous 21 days

          5. One rt-PA instillation per catheter (i.e. we will only document the results of 1 rt-PA
             instillation per catheter. Numerous rt-PA instillations in the same catheter will NOT
             be considered new events, and not entered into the study)

        Exclusion Criteria:

          1. Critically ill patients in the ICU setting.

          2. Contraindications / cautions with alteplase use including: known hypersensitivity to
             alteplase or its components (l-arginine, phosphoric acid, polysorbate 80), patients
             with known conditions associated with bleeding events (e.g.intracranial bleed in last
             4 weeks, major hemorrhage in last 4 weeks (Hgb drop of 20 g/L)), recent surgery (&lt;48
             hours), recent biopsy (&lt;48 hours), hemostatic defects including severe hepatic
             disease, or current intracranial / intraspinal neoplasm.

          3. Hemodialysis catheter has been in the patient less than 14 days.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lavern M Vercaigne, Pharm.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba</affiliation>
  </overall_official>
  <overall_official>
    <last_name>James M Zacharias, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Manitoba, Internal Medicine, Section of Nephrology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Brandon General Hospital</name>
      <address>
        <city>Brandon</city>
        <state>Manitoba</state>
        <zip>R7A 2B3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seven Oaks Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2V 3M3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Sciences Centre</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3A 1R9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 1Y3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Grand River Hospital</name>
      <address>
        <city>Kitchener</city>
        <state>Ontario</state>
        <zip>N2G 1G3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thunderbay Regional Health Sciences Centre</name>
      <address>
        <city>Thunderbay</city>
        <state>Ontario</state>
        <zip>P7B 6V4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maisonneuve Rosemont Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Zacharias JM, Weatherston CP, Spewak CR, Vercaigne LM. Alteplase versus urokinase for occluded hemodialysis catheters. Ann Pharmacother. 2003 Jan;37(1):27-33.</citation>
    <PMID>12503929</PMID>
  </reference>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 15, 2006</study_first_submitted>
  <study_first_submitted_qc>March 15, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2006</study_first_posted>
  <last_update_submitted>December 17, 2008</last_update_submitted>
  <last_update_submitted_qc>December 17, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2008</last_update_posted>
  <responsible_party>
    <name_title>Lavern M. Vercaigne</name_title>
    <organization>University of Manitoba</organization>
  </responsible_party>
  <keyword>catheter</keyword>
  <keyword>hemodialysis</keyword>
  <keyword>dysfunction</keyword>
  <keyword>thrombolytic</keyword>
  <keyword>alteplase</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

